Trailer Wizards Joins TIP Group
30.12.2019 16:00:00 EET | Business Wire | Press release
TIP Trailer Services, a portfolio company of I Squared Capital and one of the leading trailer leasing, rental, maintenance and repair providers across Europe and Canada, today announces it has completed the acquisition of Trailer Wizards, a leading supplier of trailer rental and leasing services in Canada. This follows the announcement of 4 September 2019 on the signing of the agreement for the acquisition.
Following the acquisition, TIP will integrate Trailer Wizards with its existing Canadian business, Train Trailer Rentals. This puts TIP in a strong position for long-term growth as it further strengthens its position in the Canadian market. The acquisition diversifies both the geographical footprint across Canada with the expansion of operations to new provinces and the service segment with more specialized trailers.
“After the recent acquisition of PEMA in Europe, the acquisition of Trailer Wizards is another key milestone in the growth path of TIP,” said Bob Fast, President and CEO of TIP Trailer Services. “By joining the teams of Trailer Wizards and Train Trailer Rentals, we can provide the best in flexible commercial trailer fleet solutions and pursue growth opportunities for the combined businesses. We intend to invest to develop our longstanding customer relationships with world-class transport, logistics, and retail customers in Canada.”
TIP’s Canadian division will have a combined fleet of over 33,000 trailers, reefers, chassis and flatbed or drop-deck configurations. The combined business will employ over 500 people, including approximately 300 mechanics, throughout almost 30 locations in Canada from Prince Edward Island to British Columbia.
The management of the combined business is working together on an integration plan to allow a smooth transition. Unless communicated otherwise, existing contracts, services, terms and conditions and processes will remain in place at each of the businesses.
About TIP Trailer Services
Founded in 1968, TIP Trailer Services is an equipment service provider specializing in trailer leasing, rental, maintenance and repair, as well as other value-added services to transportation and logistics customers across Europe and Canada. The company has one of the largest and most diverse trailer rental and leasing fleets with over 120,000 units. Headquartered in Amsterdam, TIP has over 2,700 employees and services its customers from 120 locations in 18 countries across Europe and Canada. For more information, please visit: https://www.tipeurope.com
About Trailer Wizards
Founded in 1963, Trailer Wizards is Canada’s largest national commercial trailer rental, leasing, sales, service parts, and storage company. Today, Trailer Wizards has 21 locations spanning Canada coast-to-coast including 14 fully staffed customer care centers. For more information, please visit: https://trailerwizards.com
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20191230005029/en/
Contact information
TIP Europe
Media
Marc Aandeweg
Vice President Sales & Marketing
T +31 (0)20 504 – 1767
M +31 (0)613 114293
E marc.aandeweg@tipeurope.com
Investor Relations
Kapil Sharma
Treasury and Investor Relations Director
T +31 (0)20 504 1677
M +31 (0)621 105358
E kapil.sharma@tipeurope.com
Trailer Wizards
Saroj Motwani
Senior Marketing & Communications Specialist
+1 905 740 3925
saroj.motwani@trailerwizards.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 20:52:00 EEST | Press release
International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he has served as pro bono counsel to five Nobel Peace Prize laureates. The New York Times has referred to him as "The Extractor" for his work freeing political prisoners worldwide. Genser's decision to support Yim Leak's team comes as the businessman faces an asset freeze exceeding 20 billion baht (more than U
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 18:38:00 EEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli ® (Relacorilant)18.9.2026 15:00:00 EEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu ® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 15:00:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at the 2025 European Society for Medical Oncology (#ESMO25) Congress and subsequently published in The New England Journal of Medicine. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In DES
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca ® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 13:58:00 EEST | Press release
Alfasigma S.p.A, a global pharmaceutical company with a focus on innovation in rare disease and specialty care in areas where there is significant unmet patient need, today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for Jyseleca® (filgotinib), an oral, once-daily JAK1 preferential inhibitor, for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy. Following this positive opinion, the application is now referred to the European Commission (EC) for final action. The EC’s decision is expected in the next weeks. “At present, half of people living with axSpA fail to adequately respond to treatment, leaving them with years of preventable struggle with persistent pain and other impactful symptoms,” said Daniele D'Ambrosio, Chief Development Officer, Alfasigma. “This
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom